
---
title: '公告精选：众生药业子公司口服抗新冠病毒创新药RAY1216临床试验获批'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=8467'
author: 证券时报网
comments: false
date: Sun, 15 May 2022 19:16:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=8467'
---

<div>   
<p>证券时报e公司讯，<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ002771" style="color: #2f67d1;text-decoration: none;" code="002771" target="_blank">真视通</a>：为上海浦东新区承建部分核酸采样工作站 订单预计确认营收占比较小；<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ002317" style="color: #2f67d1;text-decoration: none;" code="002317" target="_blank">众生药业</a>：子公司口服抗新冠病毒创新药RAY1216临床试验获批；<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS600136" style="color: #2f67d1;text-decoration: none;" code="600136" target="_blank">ST明诚</a>：2023年亚洲杯易地举办将对子公司FMA的经营造成较大影响；<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS600763" style="color: #2f67d1;text-decoration: none;" code="600763" target="_blank">通策医疗</a>：收购<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ300550" style="color: #2f67d1;text-decoration: none;" code="300550" target="_blank">和仁科技</a>29.75%股份 将成为第一大股东；<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ002693" style="color: #2f67d1;text-decoration: none;" code="002693" target="_blank">双成药业</a>：董事、高管拟减持公司股份；<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ000035" style="color: #2f67d1;text-decoration: none;" code="000035" target="_blank">中国天楹</a>：与国网江苏综能就重力储能技术研究与项目开发相关事宜达成战略合作；<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ300125" style="color: #2f67d1;text-decoration: none;" code="300125" target="_blank">聆达股份</a>：实际控制人可能变更。</p>

                  
</div>
            